Delhi · Gurugram · Bangalore · Baddi · Bahadurgarh

Particulate Matter Testing for Medical Devices

Particles that enter the bloodstream from an injectable product or a device fluid pathway can cause phlebitis, granulomas, and embolic events — so particulate matter is a firm-limit safety parameter on every injectable-pathway device. Auriga Research provides NABL-accredited particulate matter testing for IV sets, transfusion sets, syringes, catheters, blood bags, and drug-device combination products, covering sub-visible and visible particulates under the pharmacopoeial and device standards.

Our scope covers sub-visible particulates per USP <788> — both Method 1 (light obscuration, HIAC liquid particle counter) and Method 2 (microscopic membrane count) — visible particulates per USP <790>, ophthalmic particulates per USP <789>, and ISO 8536 / ISO 1135 fluid-pathway contamination testing for infusion and transfusion equipment. For combination products, we add ICP-MS elemental characterisation to trace metallic particles back to their process source.

Backed by the Arbro Group's analytical heritage — Arbro Lab since 1990, Auriga Research since 2007 — with NABL ISO/IEC 17025 accreditation, our reports are accepted by CDSCO licensing authorities, FDA 510(k) reviewers, and EU CE Notified Bodies, and are formatted for direct attachment to the product-safety / sterility section of the technical file alongside extractables and sterility data.

Reports in 7–10 working days | Routine batch release: 5–7 days | Express available

Get a Quote Call +91-7428116100

Particulate Matter Testing Scope

Each capability is mapped to its pharmacopoeial chapter or device standard so QA and regulatory teams can match scope to the submission at a glance.

USP <788>

Sub-Visible — Light Obscuration

Method 1 (light obscuration, HIAC liquid particle counter) — the primary screen for ≥ 10 µm and ≥ 25 µm sub-visible particle counts in injections and fluid pathways.

USP <788>

Sub-Visible — Microscopy

Method 2 (microscopic membrane count) — the referee method used when light obscuration is inconclusive or the product matrix interferes.

USP <790>

Visible Particulates

100% visual inspection requirement for injections and fluid-path products to be "essentially free" of visible particulates.

USP <789>

Ophthalmic Particulates

Particulate matter limits and counting for ophthalmic solutions per USP <789>.

USP <1788>

Method Guidance

Supporting guidance per USP <1788.1> (light obscuration) and <1788.2> (microscopy) for method selection and validation.

IP / Ph. Eur.

Pharmacopoeial Equivalents

Indian Pharmacopoeia 2.9.19 / 2.9.20 and Ph. Eur. equivalents where the submission market requires them.

ISO 8536

Infusion Fluid Pathway

Fluid-pathway contamination index for infusion equipment — device flushed with particle-free water and analysed by light obscuration.

ISO 1135

Transfusion Fluid Pathway

Fluid-pathway particulate contamination for transfusion equipment and components per ISO 1135.

ICP-MS

Elemental Particulate ID

Elemental quantification of metallic particulates (stainless steel, tungsten, aluminium) for drug-device combination products.

SEM-EDS

Morphological Source ID

Microscopy / SEM-EDS characterisation to trace a particle population to its process source — needle, plunger, glass, or closure.

Validation

Method Validation

Method validation and product-interference assessment to qualify the counting method for your specific device or product matrix.

How It Works

Get a Quote

Share your product type (injectable, IV / transfusion set, syringe, catheter, blood bag, combination product), the standard you need (USP <788> / <790>, ISO 8536 / 1135, IP), and your regulatory target (CDSCO / FDA / CE). Your dedicated SPOC confirms the method (light obscuration vs microscopy), whether elemental ICP-MS is needed, and the sample quantity before you dispatch anything.

Send Your Sample

Dispatch finished units (or the fluid-pathway devices) in intact primary packaging with a completed Test Request Form to the nearest Auriga lab. Each sample is individually bar coded and registered in YLIMS, Auriga's in-house Laboratory Information Management System, upon receipt. Testing begins within 24 hours of sample registration.

Testing and QA Review

Your samples are tested under controlled low-particulate conditions by Auriga's team — light obscuration on the HIAC counter, microscopic membrane count where Method 2 applies, ISO 8536 / 1135 flush testing for fluid pathways, and ICP-MS / SEM-EDS for elemental source ID. Every count passes a formal internal QA review against the applicable limit before the report is generated.

Receive Your NABL Report

Your NABL-accredited particulate matter report is delivered digitally within the committed turnaround time. Reports carry Auriga's NABL accreditation under ISO/IEC 17025:2017, cite the exact USP chapter / ISO standard and edition applied, and are accepted by CDSCO, FDA 510(k), and CE Notified Bodies. You can track sample status in real time through YLIMS.

Turnaround Time

Service	Standard TAT	Express
Sub-visible by light obscuration (USP <788> Method 1)	5–7 business days	Available
Microscopic membrane count (USP <788> Method 2)	7–10 business days	On request
Visible particulates (USP <790>)	5–7 business days	Available
ISO 8536 / ISO 1135 fluid-pathway contamination	7–10 business days	On request
Elemental particulate ID by ICP-MS / SEM-EDS	10–14 business days	On request
Method validation / interference assessment	15–20 business days	On request
Gap-fill / regulatory response addendum	48–72 hours	Express only

Who Needs Particulate Matter Testing

IV set, infusion set, and burette set manufacturers needing ISO 8536 fluid-pathway particulate data for CDSCO / BIS.
Transfusion set and blood-bag manufacturers needing ISO 1135 / USP <788> particulate data alongside their IS 12065 work.
Syringe and prefilled-syringe manufacturers running USP <788> / <790> release on the fluid path and barrel.
Catheter, cannula, and fluid-contact device manufacturers verifying particulate shedding from the lumen.
Drug-device combination product developers (autoinjectors, cartridges, on-body delivery) needing elemental particulate ID.
Injectable / parenteral manufacturers running USP <788> + <790> batch release on the drug product itself.
Ophthalmic product manufacturers requiring USP <789> particulate compliance.
Quality teams running routine particulate monitoring and trending for process control.
Regulatory consultants assembling CDSCO Form MD-9 / MD-15, FDA 510(k), and EU MDR technical files.
Post-market complaint investigation teams identifying fibres, glass, or metallic particles in returned units.

Why Auriga for Particulate Matter Testing

NABL scope covering USP <788> and ISO 8536

Particulate matter testing is explicitly listed on our NABL scope certificate under USP <788> / <790> and the ISO 8536 / 1135 fluid-pathway methods — not a derivative. CDSCO, FDA, and CE Notified Bodies accept the report without follow-up scope verification.

Both USP <788> methods in-house

Light obscuration (HIAC liquid particle counter) for routine screening and microscopic membrane count for the Method 2 referee test — both qualified in our controlled low-particulate environment, so an inconclusive light-obscuration result is resolved without a second-lab handover.

Elemental source ID for combination products

ICP-MS and morphological (microscopy / SEM-EDS) characterisation trace a metallic particle to its process source — tungsten, stainless steel, aluminium, or glass — linking the particulate result to the E&L and elemental-impurities dataset.

Bundled with E&L, sterility, and blood-bag work

Particulate matter is requested alongside extractables, sterility, and (for blood bags / IV sets) IS 12065 testing — Auriga runs them under one project lead, eliminating the data-reconciliation overhead of split-lab programmes.

CDSCO / FDA / CE acceptance trail

Reports routinely accepted in CDSCO Form MD-9 / MD-15 submissions, FDA 510(k) product-safety sections, and CE technical files reviewed by major Notified Bodies.

Arbro Group analytical heritage

Established analytical heritage through the Arbro Group (Arbro Lab since 1990, Auriga Research since 2007), with NABL ISO/IEC 17025 accreditation — the audit trail injectable-device, IV-set, and combination-product manufacturers look for in a particulate-testing partner.

Related Services

Frequently Asked Questions

What is particulate matter testing and why is it required for medical devices?

Particulate matter testing detects and counts foreign particles — sub-visible (typically 2–100 µm) and visible (≥ 50–100 µm) — in injectable products, the fluid pathway of infusion and transfusion devices, and the rinse / extract of any device that contacts a sterile fluid path. Particulates that enter the bloodstream can cause phlebitis, granulomas, embolic events, and immune reactions, so USP, the Indian Pharmacopoeia, and the device standards set firm limits. CDSCO, FDA, and EU MDR require particulate data for injectable-pathway devices (IV sets, transfusion sets, syringes, catheters, blood bags) before market release.

What is the difference between USP <788>, USP <789>, and USP <790>?

USP <788> — Particulate Matter in Injections — covers sub-visible particulates by two methods: Method 1 (light obscuration, the HIAC liquid particle counter) is the primary screen, and Method 2 (microscopic membrane count) is the referee method used when light obscuration is inconclusive or the product interferes. USP <790> — Visible Particulates in Injections — is the 100% visual inspection requirement for "essentially free" of visible particulates. USP <789> covers particulate matter in ophthalmic solutions specifically. For methods, USP <1788> (and its sub-chapters <1788.1> light obscuration / <1788.2> microscopy) gives the supporting guidance. Auriga runs all of these, with Indian Pharmacopoeia 2.9.19 / 2.9.20 and Ph. Eur. equivalents where the submission market requires them.

How does ISO 8536 apply to particulate testing of infusion and transfusion equipment?

ISO 8536 (infusion equipment for medical use) and the related ISO 1135 (transfusion equipment) specify a particulate contamination limit on the fluid pathway of infusion sets, transfusion sets, and their components. The device is flushed with a defined volume of particle-free water under controlled conditions, and the rinse is analysed by light obscuration against the ISO contamination index limit. This is distinct from the USP <788> injectable limit — it characterises particles the device itself sheds into the fluid path during use. Auriga performs the ISO 8536 / ISO 1135 fluid-pathway particulate test alongside the USP injectable-product test where both apply.

Do you test elemental (metallic) particulates for drug-device combination products?

Yes. For drug-device combination products — prefilled syringes, autoinjectors, cartridges, and on-body delivery systems — particulate characterisation increasingly requires elemental identification of metallic particles (stainless steel, tungsten from needle forming, aluminium from crimping). Auriga combines light-obscuration counting with morphological characterisation (microscopy / SEM-EDS where available) and ICP-MS for elemental quantification, so a particulate excursion can be traced to a specific process source — needle, plunger, glass, or closure. This links the particulate data to the extractables & leachables and elemental-impurities (USP <232>/<233>) dataset for a complete combination-product file.

What sample quantity is required for a particulate matter programme?

Sample quantity depends on the method and product. USP <788> light obscuration on small-volume injections pools units to make up the test volume — typically 10–25 units depending on fill volume. USP <790> visible inspection is performed on a statistically sampled set of finished units (often 20+). ISO 8536 / ISO 1135 fluid-pathway testing needs 3–10 devices per the flush protocol. Method validation / interference testing adds 10–20 units. Confirm exact quantities with your SPOC at the quote stage, particularly for low-fill-volume or high-value combination products.

What is the regulatory consequence of inadequate particulate data on a submission?

Particulate matter is a recurring deficiency category for injectable-pathway devices. (1) CDSCO MD-9 / MD-15 applications without USP <788> / <790> or ISO 8536 fluid-pathway data are returned with a sterility-assurance or product-safety deficiency — typically blocking the registration by 3–6 months. (2) FDA 510(k) submissions with thin particulate sections trigger an Additional Information (AI) request. (3) EU MDR technical files lacking particulate conformity for fluid-pathway devices are a Notified Body non-conformance. (4) Post-market: a visible-particulate complaint (fibres, glass, metal in an IV set or syringe) triggers CDSCO Materiovigilance / FDA MAUDE reporting and a recall — and the root-cause investigation requires light-obscuration trend data and elemental identification of the offending particle. A routine particulate monitoring programme is materially cheaper than reacting to a field complaint.

Can Auriga support contesting a CDSCO, FDA, or Notified Body finding on particulates with additional data?

Yes. Gap-fill particulate testing in response to a CDSCO deficiency, FDA AI request, or Notified Body non-conformance is a routine workflow. The path is: (1) review the regulator's specific finding with your SPOC; (2) identify whether the gap requires additional USP <788> light-obscuration batches, a microscopic (Method 2) referee count, ISO 8536 fluid-pathway data, or elemental identification of a specific particle population; (3) run the targeted top-up programme — not a full re-characterisation; (4) issue an NABL-accredited supplementary particulate report formatted as an addendum to the original submission. Express 48–72 hour turnaround is available for time-critical regulatory response windows.

Get a Tailored Recommendation

Talk to a Testing Expert